RxDoctor Payments Data

Amelia Williams, PA

Physician Assistant · Spokane Valley, WANPI 1881921211

Payments from drug & device makers

$3,200in general payments, 2019–2025

Across 94 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$955
  • Janssen Scientific Affairs, LLC$864
  • Johnson & Johnson$448
  • Pfizer$328
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • Lilly USA, LLC$117
  • plus $368 from 10 others

What the payments were for

  • Food & beverage$3,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,200 in reported general payments places this provider in the 90th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$29,051
Medicare patients
112
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab168$4,413,744
Skyrizi On-BodyRisankizumab-Rzaa59$1,164,545
EntyvioVedolizumab67$558,235
Humira(Cf) PenAdalimumab51$451,820
SkyriziRisankizumab-Rzaa19$215,858
RinvoqUpadacitinib24$200,319
Entyvio PenVedolizumab17$101,323
Mesalamine70$58,454
MotegrityPrucalopride Succinate11$6,506
Budesonide DrBudesonide29$5,168
Omeprazole58$956
Famotidine59$291
Esomeprazole Magnesium13$156
Prednisone23$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$448$4,413,744168 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$120$564,74178 claims
AbbVieSkyrizi, Rinvoq$955$416,17743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →